Skip to main content

GNPX

Stock
Health Care
Biotechnology

Performance overview

GNPX Price
Price Chart

Forward-looking statistics

Beta
1.36
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Company info

SectorHealth Care
IndustryBiotechnology
Employees25
Market cap$5.1M

Fundamentals

Enterprise value$5.1M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.74
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$894K
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth+10.5
Credit+0.1
Liquidity-2.9
Inflation+3.0
Commodities+0.6
Interest Rates+0.7

Valuation

Dividend yield0.00%
PEG Ratio-0.12
Price to sales
P/E Ratio-0.12
Enterprise Value to Revenue
Price to book1.75

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.

Zacks Investment Research (April 4, 2024)
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting

The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck & Co Inc's (NYSE: MRK) Keytruda for unresectable stage III or IV non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda.

Benzinga (January 3, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free